A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain.
The identification of antibody variable regions in the heavy (VH) and light (VL) chains from hybridomas is necessary for the production of recombinant, sequence-defined monoclonal antibodies (mAbs) and antibody derivatives. This process has received renewed attention in light of recent reports of hy...
Guardado en:
Autores principales: | Ghasidit Pornnoppadol, Boya Zhang, Alec A Desai, Anthony Berardi, Henriette A Remmer, Peter M Tessier, Colin F Greineder |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2422a6f031f8494c9006d47c01d9a2c4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
- Hybridoma
-
Hybridoma and hybridomics
Publicado: (2001) -
Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
por: Karina E. Zatolochina, et al.
Publicado: (2021) -
Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase
por: Kanasap Kaewchim, et al.
Publicado: (2021) -
Immunogenomic engineering of a plug-and-(dis)play hybridoma platform
por: Mark Pogson, et al.
Publicado: (2016)